Evaluating Research Inefficiencies in Randomized Clinical Trials for Endoscopic Resection of Gastrointestinal Lesions: A Cross-Sectional Analysis of ClinicalTrials.gov - Top-Institutions - MDSpire

Evaluating Research Inefficiencies in Randomized Clinical Trials for Endoscopic Resection of Gastrointestinal Lesions: A Cross-Sectional Analysis of ClinicalTrials.gov

  • By

  • Yun Dai

  • Xue-Ting Li

  • Yong-Shen Zheng

  • Jin-Hai Chen

  • Guo-Xing Xu

  • Hai-Xing Wang

  • December 3, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Surgical Oncology
    • Clinical Research

  • #2

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Endoscopic Surgery
    • Clinical Trials

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Gastroenterology
    • Surgical Oncology
    • Clinical Research

  • #4

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Endoscopic Surgery
    • Clinical Trials

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Endoscopic Surgery
    • Clinical Research

Original Source(s)

Evaluating Research Inefficiencies in Randomized Clinical Trials for Endoscopic Resection of Gastrointestinal Lesions: A Cross-Sectional Analysis of ClinicalTrials.gov

  • by Yun Dai, Xue-Ting Li, Yong-Shen Zheng, Jin-Hai Chen, Guo-Xing Xu, Hai-Xing Wang

  • December 3, 2025

Related Content

Reduced Medicaid Retroactive Eligibility and Out-of-Pocket Costs for Patients With Gastrointestinal Cancer

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

Biomarkers Expand Precision in CRC

Emerging biomarkers guide colorectal cancer diagnosis, stratification, and treatment selection